mRNA-LNP vaccination induces microenvironment remodeling and generation of tissue‑resident memory T cells in glioblastoma
Glioblastoma remains highly refractory to immunotherapy, in part because of a profoundly immunosuppressive tumour microenvironment that limits effective T-cell responses. Although mRNA vaccines can induce anti-tumour immunity, how they reshape the glioblastoma immune ecosystem to support durable tumour control is not well understood. Here we use an immunocompetent EGFRvIII-driven syngeneic glioblastoma model and antigen-specific mRNA lipid nanoparticle (mRNA-LNP) vaccination to define the cellular and spatial mechanisms underlying therapeutic response. In our model, vaccination induced durable EGFRvIII-specific humoral and cellular immunity, resulting in complete tumour eradication and long-term protection against intracranial rechallenge. Integrative analyses incorporating flow cytometry, tumour interstitial fluid profiling, multiplex immunostaining, spatial transcriptomics and ligand-receptor modelling demonstrated extensive remodelling of the tumour microenvironment following vaccination. Early tumour control was associated with expansion of pro-inflammatory and antigen-presenting myeloid populations, increased cytotoxic CD8⁺ T-cell infiltration and activation, enhanced interferon-responsive signalling, and the formation of immune-supportive spatial niches enriched for antigen presentation and chemokine-mediated cellular communication. Vaccination promoted inflammatory chemokine relay networks centred on the CXCL16-CXCR6 axis, a pathway linked to tissue residency programming in the central nervous system. Functional depletion studies identified CD4⁺ and CD8⁺ T cells as essential mediators of therapeutic efficacy, while durable protection was maintained by tumour-specific brain-resident memory CD8⁺ T cells that persisted despite peripheral lymphocyte depletion. Together, these findings identify T-cell-driven microenvironmental remodelling as a critical mechanism linking mRNA vaccination to the establishment of long-term brain-resident anti-tumour immunity in glioblastoma.
Authors
- Douglas J. Mahoney (ORCID: https://orcid.org/0000-0002-0642-992X)
- Judy Wang (ORCID: https://orcid.org/0000-0002-7355-7542)
- Xueqing Q. Lun (ORCID: https://orcid.org/0000-0001-9728-2996)
- Yilin Tan (ORCID: https://orcid.org/0000-0003-2958-978X)
- A. Sorana Morrissy (ORCID: https://orcid.org/0000-0001-8526-562X)
- Kristofor K. Ellestad (ORCID: https://orcid.org/0000-0001-9350-4977)
- Jennifer Ai-wen Chan (ORCID: https://orcid.org/0000-0001-9798-1551)
- Joanna Pyczek (ORCID: https://orcid.org/0000-0002-0157-2049)
- Rajesh G. Krishnan (ORCID: https://orcid.org/0000-0002-9171-3422)
- Robert Nechanitzky (ORCID: https://orcid.org/0000-0002-0429-0688)
- Natalia Martín‐Orozco (ORCID: https://orcid.org/0000-0002-4033-3577)
- Yury Karpov
- Matthew J. Gold (ORCID: https://orcid.org/0009-0009-3294-2952)
- Kirsten Olsen
- Haritha Menon
- Shannon Marissa Hubert Snelling
- Jun Liu
- Yu Wu
- Varsha Thoppey Manoharan
- Anushka Patel
Institutions
- University of Calgary (CA)
- University of Toronto (CA)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-13
- DOI
- https://doi.org/10.64898/2026.11.11.762754
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- preprint
Funders
- Calgary Foundation
- Alberta Cancer Foundation